Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-08-13

Clinical Trial Update: A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C [Phase 1]

View source ↗

Summary

Phase 1 study evaluating GS-9620 in treatment-naive subjects with chronic hepatitis C has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • GS-9620 (vesatolimod)

Snippet

Sponsor: Gilead Sciences | Conditions: Hepatitis C | Phase 1 | Status: COMPLETED